<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FINANCIAL STATEMENTS OF ARONEX PHARMACEUTICALS, INC. SET FORTH IN THE COMPANY'S FORM 10-Q FOR THE NINE MONTHS ENDED SEPTEMBER 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <PERIOD-TYPE> 9-MOS <FISCAL-YEAR-END> DEC-31-1998 <PERIOD-END> SEP-30-1999 <CASH> 15,884,000 <SECURITIES> 8,442,000 <RECEIVABLES> 857,000 <ALLOWANCES> 0 <INVENTORY> 0 <CURRENT-ASSETS> 24,823,000 <PP&E> 5,445,000 <DEPRECIATION> 3,319,000 <TOTAL-ASSETS> 27,876,000 <CURRENT-LIABILITIES> 4,354,000 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 23,000 <OTHER-SE> 19,881,000 <TOTAL-LIABILITY-AND-EQUITY> 27,876,000 <SALES> 0 <TOTAL-REVENUES> 11,757,000 <CGS> 0 <TOTAL-COSTS> 0 <OTHER-EXPENSES> 18,805,000 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 257,000 <INCOME-PRETAX> (7,305,000) <INCOME-TAX> 0 <INCOME-CONTINUING> (7,305,000) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (7,305,000) <EPS-BASIC> (0.34) <EPS-DILUTED> (0.34)